NAION – Medxy AI

GLP-1 Weight-Loss and Diabetes Drugs: What Eye Specialists Say About NAION Risk

By MedXY 05/18/2026

A new consensus statement advises cautious, shared decision-making about GLP-1 receptor agonists and NAION risk, noting that current evidence is observational, conflicting, and suggests any absolute risk increase is small.

Clinical Updates Diabetes & Endocrinology news Ophthalmology

Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: Synthesizing Evidence from Target Trial Emulations and Global Pharmacovigilance

By MedXY 04/02/2026

This review synthesizes recent evidence regarding the association between semaglutide initiation and nonarteritic anterior ischemic optic neuropathy (NAION), contrasting high-risk findings in real-world cohort studies with neutral findings in RCT meta-analyses and exploring potential mechanistic pathways.

news Ophthalmology

Neuroprotection in NAION: QPI-1007 Fails Primary Endpoint but Shows Promise in Severe Vision Loss

By MedXY 02/04/2026

This Phase 2/3 trial of QPI-1007 for NAION found that while the primary endpoint was not met for the general population, the siRNA therapy significantly preserved vision in patients with more severe baseline visual impairment.

Clinical Updates news Ophthalmology Otorhinolaryngology Specialties

GLP-1 Receptor Agonists Linked to Early Risk of Optic Nerve Damage: A Case-Control Study Analysis

By MedXY 07/30/2025

GLP-1 receptor agonist use, especially liraglutide, is associated with a higher risk of nonarteritic anterior ischemic optic neuropathy (NAION) during the first year, particularly in patients without diabetes or obesity.